Clinical Trial Update: A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database

View source ↗

Summary

A post-marketing safety study in Denmark evaluated abatacept (Orencia) for rheumatoid arthritis and psoriatic arthritis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• ORENCIA (ABATACEPT)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) | Status: COMPLETED